Chemical king DuPont
Wall Street Wisdom:
- General consensus. Fifteen analysts follow DuPont, of whom 11 rate the company a "buy," with the rest voting "hold." Not a "sell" in sight.
- Revenues. Here's something you don't see often. A year ago, DuPont made $6.03 billion in sales. The analysts' prediction for tomorrow? $6.03 billion once again.
- Earnings. Unfortunately, the same doesn't hold true for earnings. Analysts expect them to plunge 73% versus last year, to just $0.10 per share.
Margin watch:
Reviewing the company's recent performance in transforming top-line sales into bottom-line profits, here's what we see:
Margins |
6/04 |
9/04 |
12/04 |
3/05 |
6/05 |
9/05 |
---|---|---|---|---|---|---|
Gross |
27% |
27.8% |
28.1% |
29.3% |
30.2% |
30% |
Op. |
10.8% |
11.7% |
11.5% |
12.6% |
13.4% |
13% |
Net |
3.2% |
7.4% |
6.3% |
7.5% |
9.3% |
7.7% |
Can you say "turnaround"? Things don't look so hot consecutively over the past two quarters, but when compared to their year-ago equivalents, DuPont is showing signs of life. Keep a sharp eye out for more of those on the morrow. (Learn more about margins.)
Valuation:
DuPont sports a trailing P/E of 18, but beware. On a free cash flow basis, this company's positively acidic, with a price-to-free cash flow ratio of 33. Either way, the company's projected growth rate of less than 10% makes these shares look overpriced today. Then again, that might just be the best time to buy a cyclical company. (Brush up on valuation.)
Competitors:
Deutschland seems uberalles of DuPont's competitive landscape. Its top two competitors are Bayer
Fool contributor Rich Smith does not own shares of any company named above. Dow Chemical is a Motley Fool Income Investor pick. The Fool has a disclosure policy .